<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>VETA-K1- phytonadione solution </strong><br>Bimeda Inc., Division of Cross Vetpharm Group<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/ComplianceEnforcement/UnapprovedAnimalDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<h1></h1>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="L4456646a-0623-493d-a002-607bc4a5c28d"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Veta-K<span class="Sub">1</span><span class="Sup">®</span> Injection</span></p>
<p><span class="Bold">(phytonadione)</span></p>
<p><span class="Bold">Aqueous Colloidal Solution</span></p>
<p><span class="Bold">10 mg/mL</span></p>
<p><span class="Bold">FOR ANIMAL USE ONLY</span></p>
<p><span class="Bold">KEEP OUT OF REACH OF CHILDREN</span></p>
<p><span class="Bold">CAUTION:</span> Federal law restricts this drug to use by or on the order of a lincensed veterinarian</p>
<p><span class="Bold">Net Contents: 100 mL</span></p>
<p><span class="Bold">Multiple Dose Vial</span></p>
<p><span class="Bold">For complete warnings and additional information see enclosed insert.</span></p>
<p><span class="Bold">DESCRIPTION:</span> Phytonadione is a vitamin, which is a clear, yellow to amber, viscous, odorless or nearly odorless liquid. It is insoluble in water, soluble in chloroform and slightly soluble in ethanol. It has a molecular weight of 450.70.</p>
<p>Phytonadione is 2-methyl-3-phytyl-1, 4-naphthoquinone. Its empirical formula is C31H46O2.</p>
<p>Veta-K<span class="Sub">1</span><span class="Sup">®</span> Injection is a yellow, sterile, aqueous colloidal solution of vitamin K<span class="Sub">1</span>, with a pH of 5.0 to 7.0, available for injection by the intravenous, intramuscular and subcutaneous routes.</p>
<p><span class="Bold">EACH mL CONTAINS:</span> Phytonadione 10 mg; Polyoxyethylated fatty acid derivative 65 mg; Dextrose monohydrate 37.5 mg; Butylated hydroxyanisole 1 mg; Butylated hydroxytoluene 1 mg; Citric acid 8.4 mg; Sodium phosphate 17.2 mg; with Benzyl Alcohol 0.9% w/v added as a preservative.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Lf72f8ac1-645f-4690-9b5e-9af9184ef8f2"></a><a name="section-2"></a><p></p>
<p class="First"><span class="Bold">CLINICAL PHARMACOLOGY:</span></p>
<p>Veta-K<span class="Sub">1</span><span class="Sup">® </span>Injection aqueous colloidal solution of vitamin K<span class="Sub">1</span> for parenteral injection, possesses the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). The <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> test is sensitive to the levels of three of these four factors-II, VII, and X.</p>
<p>Vitamin K is an essential cofactor for a microsomal enzyme that catalyzes the post-translational carboxylation of multiple, specific, peptide-bound glutamic acid residues in inactive hepatic precursors of factors II, VII, IX, and X. The resulting gamma-carboxy-glutamic acid residues convert the precursors into active coagulation factors that are subsequently secreted by liver cells into the blood.</p>
<p>Phytonadione is readily absorbed following intramuscular administration. After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues. Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine.</p>
<p>In normal animals and humans, phytonadione is virtually devoid of pharmacodynamic activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function, that is, to promote the hepatic biosynthesis of vitamin K dependent clotting factors.</p>
<p><span class="Italics">The action of the aqueous colloidal solution, when administered intravenously, is generally detectable within an hour or two and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> is usually controlled within 3 to 6 hours. A normal <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> level may often be obtained in 12 to 14 hours.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="L9795c6d7-31ab-4254-a1cd-8cd49b1c00b9"></a><a name="section-3"></a><p></p>
<p class="First"><span class="Bold">INDICATIONS: </span>Veta-K<span class="Sub">1</span><span class="Sup">® </span>Injection is indicated in <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> which are due to faulty formation of factors II, VII, IX and X when caused by <span class="product-label-link" type="condition" conceptid="435781" conceptname="Vitamin K deficiency">vitamin K deficiency</span> or interference with vitamin K activity.</p>
<p>Veta-K<span class="Sub">1</span><span class="Sup">®</span> Injection is also indicated in cattle, calves, horses, swine, sheep, goats, dogs, and cats to counter <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> induced by ingestion of anticoagulant rodenticides. Veta-K<span class="Sub">1</span><span class="Sup">®</span> Injection is also indicated to counter <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> caused by consumption of bishydroxycoumarin found in a spoiled and moldy sweet clover.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="L5f021ddf-08aa-460e-a2a7-ca2c1cff21d7"></a><a name="section-4"></a><p></p>
<p class="First"><span class="Bold">DOSAGE AND ADMINISTRATION: Cattle, Calves, Horses, Swine, Sheep, and Goats:</span> Acute <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> (with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>) and Non-acute <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> - 0.5 - 2.5 mg/kg subcutaneously OR intramuscularly.</p>
<p><span class="Bold">Dogs and Cats</span>: Acute <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> (with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>) and Non-acute <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> - 0.25 - 5.0 mg/kg subcutaneously OR intramuscularly. Use higher end of dose for second generation rodenticides.</p>
<p>Whenever possible, Veta-K<span class="Sub">1</span><span class="Sup">® </span>Injection should be given by the subcutaneous or intramuscular route. When intravenous administration is considered unavoidable, the drug should be diluted and injected very slowly, not exceeding 1 mg per minute.</p>
<p><span class="Bold">DIRECTIONS FOR DILUTION:</span> Veta-K<span class="Sub">1</span><span class="Sup">®</span> Injection may be diluted with 0.9% Sodium Chloride Injection, 5% Dextrose Injection, or 5% Dextrose and Sodium Chloride Injection. Other Diluents Should Not Be Used. When dilutions are indicated, administration should be started immediately after mixture with the diluent, and unused portions of the dilution should be discarded.</p>
<p>Whole blood or component therapy may be indicated if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is excessive. This therapy, however, does not correct the underlying disorder and Veta-K<span class="Sub">1</span><span class="Sup">®</span> Injection should be given concurrently. In the event of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> or excessive blood loss, the use of whole blood component therapy is indicated.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Lf9723690-2f1a-417f-9fd9-7d68e42783ef"></a><a name="section-5"></a><p></p>
<p class="First"><span class="Bold">CONTRAINDICATIONS:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Lfeed6b65-d276-4bea-97e1-5aa629856366"></a><a name="section-6"></a><p></p>
<p class="First"><span class="Bold">PRECAUTIONS:</span></p>
<p><span class="Bold">Drug Interactions:</span> Temporary resistance to <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span>-depressing anticoagulants may result, especially when larger doses of phytonadione are used. If relatively large doses have been employed, it may be necessary when reinstituting anticoagulant therapy to use somewhat larger doses of the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span>-depressing anticoagulant, or to use one which acts on a different principle, such as heparin sodium.</p>
<p><span class="Bold">Laboratory Tests:</span> <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be checked regularly as clinical conditions indicate.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p><span class="Bold">CAUTION:</span> Federal law restricts this drug to use by or on the order of a lincensed veterinarian.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Lb02b8c3c-faf6-4571-92eb-43be54927be1"></a><a name="section-7"></a><p></p>
<p class="First"><span class="Bold">WARNING:</span></p>
<table width="100%">
<caption><span></span></caption>
<tbody class="Headless"><tr class="First Last"><td class="Lrule Rrule"><p class="First"><span class="Bold">WARNING - INTRAVENOUS USE:</span> Severe reactions, including fatalities, have occurred during and immediately after the INTRAVENOUS injection of phytonadione, even when precautions have been taken to dilute the phytonadione and to avoid rapid infusion. Typically these severe reactions have resembled <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and cardiac and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>. Some animals have exhibited these severe reactions on receiving phytonadione for the first time. Therefore, the INTRAVENOUS route should be restricted to those situations where other routes are not feasible and the serious risk involved is considered justified.</p></td></tr></tbody>
</table>
<p>An immediate coagulant effect should not be expected after administration of phytonadione. <span class="Italics">A minimum of 1 to 2 hours is required for measurable improvement in the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</span> Whole blood or component therapy may also be necessary if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is severe.</p>
<p>Phytonadione will not counteract the anticoagulant action of heparin.</p>
<p>When vitamin K<span class="Sub">1</span> is used to correct excessive anticoagulant-induced <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>, anticoagulant therapy still being indicated, the patient is again faced with the clotting hazards existing prior to starting the anticoagulant therapy. Phytonadione is not a clotting agent, but overzealous therapy with vitamin K<span class="Sub">1</span> may restore conditions which originally permitted thromboembolic phenomena. Dosage should be kept as low as possible, and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be checked regularly as clinical conditions indicate.</p>
<p>Repeated large doses of vitamin K are not warranted in liver disease if the response to initial use of the vitamin is unsatisfactory. Failure to respond to vitamin K may indicate that the condition being treated is inherently unresponsive to vitamin K.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="L8dfc3a0a-e8cf-49e3-9b62-e1d87a2a9a15"></a><a name="section-8"></a><p></p>
<p class="First"><span class="Bold">ADVERSE REACTIONS:</span> <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> have occured following intravenous injection. (SEE BOX WARNING). <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> at the injection site may occur. Intramuscular injection may result in <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>. The possibility of allergic sensitivity, including an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, should be kept in mind.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="Lfd7bf662-28c4-4fff-b79c-016f9aec68c6"></a><a name="section-9"></a><p></p>
<p class="First"><span class="Bold">STORAGE:</span> Protect from light at all times. Store in a dark place at controlled room temperature between 15° and 30° C (59° - 86° F).</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="L16d8576a-7d2d-4692-9863-3fbaf4835bec"></a><a name="section-10"></a><p></p>
<p class="First"><img alt="label.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b08d2ba5-c3c5-47ce-a9d6-64d7cee9483b&amp;name=label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VETA-K1 		
					</strong><br><span class="contentTableReg">phytonadione solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61133-6003</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS, INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PHYTONADIONE</strong> (PHYTONADIONE) </td>
<td class="formItem">PHYTONADIONE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61133-6003-1</td>
<td class="formItem">100 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">10/07/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bimeda Inc., Division of Cross Vetpharm Group
							(060492923)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Bimeda Inc., Division of Cross Vetpharm Group (060492923)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bimeda-MTC Division of Cross Vetpharm Group</td>
<td class="formItem"></td>
<td class="formItem">256232216</td>
<td class="formItem">manufacture</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Shandong Guagtongbao Pharmaceutical's</td>
<td class="formItem"></td>
<td class="formItem">526893588</td>
<td class="formItem">api manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b874aa50-ae61-444f-b17c-4e432448419a</div>
<div>Set id: b08d2ba5-c3c5-47ce-a9d6-64d7cee9483b</div>
<div>Version: 2</div>
<div>Effective Time: 20130903</div>
</div>
</div> <div class="DistributorName">Bimeda Inc., Division of Cross Vetpharm Group</div></p>
</body></html>
